OSE Immunotherapeutics present significant data on Selective Anti-SIRPa OSE-172 (Effi-DEM)
OSE Immunotherapeutics announced that the Company presented in oral session significant data on Selective Anti-SIRPa OSE-172 (Effi-DEM), at the “2nd Annual Advances in Immuno-Oncology Congress” in London on May 15, 2017.
OSE-172 (Effi-DEM) is a humanized monoclonal antibody targeting SIRPa, expressed on suppressive myeloid cells (Myeloid Derived Suppressor Cells, MDSC and Tumor Associated Macrophages, TAM) as well as effector myeloid cells (anti-tumoral macrophages) involved in the Tumor Micro-Environment. As a selective antagonist of SIRPa, OSE-172 promotes recruitment of effector over suppressive myeloid cells, in particular it inhibits M2 pro-tumorigenic macrophage cells and increases M1 anti-tumorigenic cells, whilst increasing effector memory CD8 T-cells resurrecting key immune defenses.
OSE-172 does not bind to red blood cells and platelets constituting a potential hematologic safety advantage.
“Our myeloid checkpoint inhibitor OSE -172demonstrates its strong impacton the Tumor Micro-Environment beyond myeloid cells, tackling cancer through a specific blockade of SIRPa,” said Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics.
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
OSE Immunotherapeutics announced the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and Riad Abès, Ph.D., as CMC Project Manager, further strengthening the Company’s R&D team, based in Nantes.
« We are pleased to welcome Aurore and Riad to the OSE Immunotherapeutics team. With their high scientific and industrial levels, these new talents will bring their experience to advance our products from preclinical to clinical phase », said Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International scientific collaborations.
Selexis and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
Selexis SA and OSE Immunotherapeutics announced the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™.
The agreement builds upon previous collaboration between the two companies as announced in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflammatory bowel diseases, such as ulcerative colitis.